NurExone Biologic Inc.
NRX.V
TSX
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -17.60% | 4.16% | -15.96% | -2.43% | 38.55% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -8.07% | 3.35% | -10.04% | 14.09% | 38.03% |
| Operating Income | 8.07% | -3.35% | 10.04% | -14.09% | -38.03% |
| Income Before Tax | 8.83% | -5.24% | 9.77% | -17.20% | -39.32% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 8.83% | -5.24% | 9.77% | -17.20% | -39.32% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 8.83% | -5.24% | 9.77% | -17.20% | -39.32% |
| EBIT | 8.07% | -3.35% | 10.04% | -14.09% | -38.03% |
| EBITDA | 9.21% | -2.66% | 10.94% | -12.00% | -36.19% |
| EPS Basic | 22.55% | 14.91% | 26.27% | 4.06% | -9.30% |
| Normalized Basic EPS | 22.45% | 14.79% | 26.47% | 4.07% | -8.89% |
| EPS Diluted | 22.55% | 14.91% | 26.27% | 4.06% | -9.30% |
| Normalized Diluted EPS | 22.45% | 14.79% | 26.47% | 4.07% | -8.89% |
| Average Basic Shares Outstanding | 17.60% | 23.67% | 22.80% | 22.13% | 27.61% |
| Average Diluted Shares Outstanding | 17.60% | 23.67% | 22.80% | 22.13% | 27.61% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |